A case of enamel renal syndrome from a novel genetic mutation, multidisciplinary management and long-term prognosis
Abstract
Background: The heterogeneous features of enamel renal syndrome (ERS) make diagnosis and treatment challenging. The main symptoms are disturbed amelogenesis and nephrocalcinosis. Bi-allelic likely pathogenic (LP) or pathogenic (P) variants in FAM20A have been associated with the syndrome since 2012. Affected patients often receive extensive dental treatment because of deviant orofacial morphology. However, knowledge about long-term prognosis and treatment guidelines are still lacking. The complex nature of ERS might endanger both dental and general health. The purpose of this article is to highlight the risks of overlooking the symptoms of the syndrome, and to discuss management strategies, surveillance and prognosis.
Case presentation: We report the management of a case with suspected ERS after initial dental treatment elsewhere with no adjustment for the syndrome. Dental treatment was revised and followed for 8 years. Complementary medical examinations were conducted, and ERS was genetically confirmed, revealing homozygosity for a LP c.755_757del, p.(Phe252del) variant in FAM20A. The nephrological investigation revealed medullary calcium deposits, normal renal function and hypophosphatemia. Urine analysis revealed hypocitraturia and hypocalciuria. Accordingly, the patient now medicates with potassium citrate to decrease the risk of progressive renal stone formation.
Conclusion: We herein describe a patient with confirmed ERS with an 8-year follow-up. Diagnostic delay until adulthood led to complicated dental treatment. The results of nephrological investigations are presented. The importance of dental and medical multidisciplinary management in syndromic disorders affecting the formation of the enamel is also exemplified. The dental prognosis after rehabilitation is likely affected by anatomical variations and patient cooperation. The prognosis for renal function seems to be good. However, lifelong surveillance of renal function is recommended.
Registration: The ethics committee in Uppsala, Sweden, determined that ethical approval was not necessary in this case (2019-04835). Informed consent was obtained from the participant in writing and is documented in the medical records.
Downloads
References
2. Rao S, Witkop CJ, Jr. Inherited defects in tooth structure. Birth Defects Orig Artic Ser. 1971;7:153–84.
3. Witkop CJ, Jr. Heterogeneity in inherited dental traits, gingival fibromatosis and amelogenesis imperfecta. South Med J. 1971;64:16–25. doi: 10.1097/00007611-197102001-00005
4. Smith CEL, Poulter JA, Antanaviciute A, Kirkham J, Brookes SJ, Inglehearn CF, et al. Amelogenesis imperfecta; genes, proteins, and pathways. Front Physiol. 2017;8:435. doi: 10.3389/fphys.2017.00435
5. Bloch-Zupan A, Rey T, Jimenez-Armijo A, Kawczynski M, Kharouf N, Dure-Molla M, et al. Next-generation sequencing sheds light on witkop’s classification. Front Physiol. 2023;14:1130175. doi: 10.3389/fphys.2023.1130175
6. Kirzioglu Z, Ulu KG, Sezer MT, Yuksel S. The relationship of amelogenesis imperfecta and nephrocalcinosis syndrome. Med Oral Patol Oral Cir Bucal. 2009;14:e579–82. doi: 10.4317/medoral.14.e579
7. de la Dure-Molla M, Quentric M, Yamaguti PM, Acevedo AC, Mighell AJ, Vikkula M, et al. Pathognomonic oral profile of enamel renal syndrome (ERS) caused by recessive fam20a mutations. Orphanet J Rare Dis. 2014;9:84. doi: 10.1186/1750-1172-9-84
8. Farias MLM, Ornela GO, de Andrade RS, Martelli DRB, Dias VO, Júnior HM. Enamel renal syndrome: a systematic review. Indian J Nephrol. 2021;31:1–8. doi: 10.4103/ijn.IJN_27_19
9. Dellow EL, Harley KE, Unwin RJ, Wrong O, Winter GB, Parkins BJ. Amelogenesis imperfecta, nephrocalcinosis, and hypocalciuria syndrome in two siblings from a large family with consanguineous parents. Nephrol Dial Transplant. 1998;13:3193–6. doi: 10.1093/ndt/13.12.3193
10. Kantaputra PN, Kaewgahya M, Khemaleelakul U, Dejkhamron P, Sutthimethakorn S, Thongboonkerd V, et al. Enamel-renal-gingival syndrome and fam20a mutations. Am J Med Genet A. 2014;164A:1–9. doi: 10.1002/ajmg.a.36187
11. Simancas Escorcia V, Guillou C, Abbad L, Derrien L, Rodrigues Rezende Costa C, Cannaya V, et al. Pathogenesis of enamel-renal syndrome associated gingival fibromatosis: a proteomic approach. Front Endocrinol (Lausanne). 2021;12:752568. doi: 10.3389/fendo.2021.752568
12. Wang SK, Reid BM, Dugan SL, Roggenbuck JA, Read L, Aref P, et al. Fam20a mutations associated with enamel renal syndrome. J Dent Res. 2014;93:42–8. doi: 10.1177/0022034513512653
13. Agha RA, Borrelli MR, Farwana R, Koshy K, Fowler AJ, Orgill DP, et al. The scare 2018 statement: updating consensus surgical case report (scare) guidelines. Int J Surg. 2018;60:132–6. doi: 10.1016/j.ijsu.2018.10.028
14. Jaureguiberry G, De la Dure-Molla M, Parry D, Quentric M, Himmerkus N, Koike T, et al. Nephrocalcinosis (enamel renal syndrome) caused by autosomal recessive fam20a mutations. Nephron Physiol. 2012;122:1–6. doi: 10.1159/000349989
15. Patel M, McDonnell ST, Iram S, Chan MF. Amelogenesis imperfecta – lifelong management. Restorative management of the adult patient. Br Dent J. 2013;215:449–57. doi: 10.1038/sj.bdj.2013.1045
16. Coffield KD, Phillips C, Brady M, Roberts MW, Strauss RP, Wright JT. The psychosocial impact of developmental dental defects in people with hereditary amelogenesis imperfecta. J Am Dent Assoc. 2005;136:620–30. doi: 10.14219/jada.archive.2005.0233
17. Poulsen S, Gjorup H, Haubek D, Haukali G, Hintze H, Lovschall H, et al. Amelogenesis imperfecta – a systematic literature review of associated dental and oro-facial abnormalities and their impact on patients. Acta Odontol Scand. 2008;66:193–9. doi: 10.1080/00016350802192071
18. Hashem A, Kelly A, O’Connell B, O’Sullivan M. Impact of moderate and severe hypodontia and amelogenesis imperfecta on quality of life and self-esteem of adult patients. J Dent. 2013;41:689–94. doi: 10.1016/j.jdent.2013.06.004
19. Pousette Lundgren G, Karsten A, Dahllof G. Oral health-related quality of life before and after crown therapy in young patients with amelogenesis imperfecta. Health Qual Life Outcomes. 2015;13:197. doi: 10.1186/s12955-015-0393-3
20. Lundgren GP, Vestlund GM, Dahllof G. Crown therapy in young individuals with amelogenesis imperfecta: long term follow-up of a randomized controlled trial. J Dent. 2018;76:102–8. doi: 10.1016/j.jdent.2018.06.020
21. Pousette Lundgren G, Dahllof G. Outcome of restorative treatment in young patients with amelogenesis imperfecta. A cross-sectional, retrospective study. J Dent. 2014;42:1382–9. doi: 10.1016/j.jdent.2014.07.017
22. Ravassipour DB, Powell CM, Phillips CL, Hart PS, Hart TC, Boyd C, et al. Variation in dental and skeletal open bite malocclusion in humans with amelogenesis imperfecta. Arch Oral Biol. 2005;50:611–23. doi: 10.1016/j.archoralbio.2004.12.003
23. Wang SK, Aref P, Hu Y, Milkovich RN, Simmer JP, El-Khateeb M, et al. Fam20a mutations can cause enamel-renal syndrome (ers). PLoS Genet. 2013;9:e1003302. doi: 10.1371/journal.pgen.1003302
24. Pêgo SPB, Coletta RD, Dumitriu S, Iancu D, Albanyan S, Kleta R, et al. Enamel-renal syndrome in 2 patients with a mutation in fam20 a and atypical hypertrichosis and hearing loss phenotypes. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;123:229–34.e2. doi: 10.1016/j.oooo.2016.09.226
25. Kantaputra PN, Bongkochwilawan C, Lubinsky M, Pata S, Kaewgahya M, Tong HJ, et al. Periodontal disease and fam20a mutations. J Hum Genet. 2017;62:679–86. doi: 10.1038/jhg.2017.26
26. Wang YP, Lin HY, Zhong WL, Simmer JP, Wang SK. Transcriptome analysis of gingival tissues of enamel-renal syndrome. J Periodontal Res. 2019;54:653–61. doi: 10.1111/jre.12666
27. Hassib NF, Shoeib MA, ElSadek HA, Wali ME, Mostafa MI, Abdel-Hamid MS. Two new families with enamel renal syndrome: a novel fam20a gene mutation and review of literature. Eur J Med Genet. 2020;63:104045. doi: 10.1016/j.ejmg.2020.104045
28. Koruyucu M, Seymen F, Gencay G, Gencay K, Tuna EB, Shin TJ, et al. Nephrocalcinosis in amelogenesis imperfecta caused by the fam20a mutation. Nephron. 2018;139:189–96. doi: 10.1159/000486607
29. Patel V, Klootwijk E, Whiting G, Bockenhauer D, Siew K, Walsh S, et al. Quantification of fam20a in human milk and identification of calcium metabolism proteins. Physiol Rep. 2021;9:e15150. doi: 10.14814/phy2.15150
30. Oliveira B, Kleta R, Bockenhauer D, Walsh SB. Genetic, pathophysiological, and clinical aspects of nephrocalcinosis. Am J Physiol Renal Physiol. 2016;311:F1243–52. doi: 10.1152/ajprenal.00211.2016
31. Poornima P, Katkade S, Mohamed RN, Mallikarjuna R. Amelogenesis imperfecta with bilateral nephrocalcinosis. BMJ Case Rep. 2013:1–3. doi: 10.1136/bcr-2013-009370
32. Erben RG. Physiological actions of fibroblast growth factor-23. Front Endocrinol (Lausanne). 2018;9:267. doi: 10.3389/fendo.2018.00267
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright of their work, with first publication rights granted to Upsala Medical Society. Read the full Copyright- and Licensing Statement.
